Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06360523Recruiting
AI-guided MRI for prostate cancer diagnosis
This trial tests if an artificial intelligence system can improve MRI scans used to detect prostate cancer. You may join if your doctor has recommended a prostate biopsy and you have an MRI scan that can be reviewed by both radiologists and AI.
Hong KongAges 18 years+ - NCT07075666Enrolling by invitation
Early detection of prostate cancer in Syrian men
This trial aims to find prostate cancer early in Syrian men living in the middle region of the country. If you join, you'll help doctors learn better ways to screen for the disease, which may lead to earlier and more effective treatment.
HomsAges 40–65 - NCT05882253Recruiting
Test MRI-guided biopsy for early prostate cancer detection
This study uses a special MRI-guided (MRI-fusion) needle biopsy to look for early prostate cancer. It may help find concerning areas more accurately before cancer spreads.
La Jolla, CaliforniaAges Any age - NCT05765500RecruitingPhase 2
Relugolix vs leuprolide to improve prostate cancer quality of life
This Phase 2 study compares two medicines that lower testosterone—relugolix tablets versus leuprolide injections—to see which better improves quality of life. It’s for people with prostate cancer who are starting hormone treatment and have not used similar testosterone-lowering drugs before.
Boston, MassachusettsAges 18 years+ - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+ - NCT06965192Recruiting
Visual tools for cancer surgeon decision-making
This trial tests visual tools to help surgeons make better decisions for patients with early-stage prostate or kidney cancer. It may help you and your doctor choose the best treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT06659614Recruiting
Prostate tissue collection for future cancer research
This study collects prostate tissue samples from men who are either at higher risk due to a gene change or are getting a biopsy or prostate surgery for routine care. The samples are stored in a biobank for future research on prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT06981377Recruiting
Prostate cancer blood test research study
This study is looking at blood samples from people with prostate cancer to better understand the disease. It may help researchers find new ways to monitor or treat prostate cancer.
Meldola, Forlì-CesenaAges 18 years+ - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT03784924Recruiting
Prostate MRI study to find blood and urine cancer signals
This study enrolls men who may have prostate cancer but do not yet have a diagnosis. It uses prostate MRI along with blood and urine tests to see if specific signals can help identify prostate cancer sooner.
Ann Arbor, MichiganAges 18 years+ - NCT07605936Recruiting
Understanding Frailty in Older Men With Prostate Cancer
This study looks at how frailty (physical weakness and loss of strength) affects older men who have been diagnosed with prostate cancer. Researchers want to understand which men are at higher risk and how this might guide better treatment decisions.
Limerick, MunsterAges 65 years+ - NCT06766526Recruiting
Online support for emotional adjustment after prostate cancer
This trial tests an online support program to help men cope with emotional distress after prostate cancer. You participate from home using a computer or smartphone.
LinköpingAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06756334RecruitingEarly Phase 1
Comparing Two PET/CT Scans for Prostate Cancer
This study compares two types of PET/CT scans (using different radioactive tracers) to see which one is better at finding prostate cancer, detecting if it has come back, or spotting spread to other parts of the body. You will get both scans so doctors can compare them directly.
Hefei, AnhuiAges 18–90 - NCT07514897Recruiting
Urine test to detect bladder cancer using CREPT protein
This study tests whether a protein called CREPT found in urine can help doctors diagnose bladder cancer or monitor patients who already have it. Researchers will compare urine samples from people with bladder cancer, people with other bladder conditions, and healthy volunteers.
Beijing, Chaoyang DistrictAges 18–75 - NCT07645391Recruiting
Early Detection Program for Men at High Genetic Risk for Prostate Cancer
This study aims to find prostate cancer early in men who have a genetic predisposition (inherited genetic mutations or strong family history) that puts them at higher risk. The goal is to detect it sooner, when treatment may be more effective.
Ann Arbor, MichiganAges 35–70 - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT06424275Enrolling by invitation
Prostate cancer screening trial for European men ages 50-69
This trial aims to raise awareness and screen for prostate cancer in men aged 50 to 69 across the European Union. You may be able to join if you have never been diagnosed with prostate cancer and haven't had a prostate biopsy or MRI in the last six months.
DublinAges 50–69
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 431 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.